A Clinicopathologic Study of Endometrial Cancer Metastatic to Bone: Identification of Microsatellite Instability Improves Treatment Strategies

Publication date: Available online 10 February 2020Source: Gynecologic Oncology ReportsAuthor(s): Jennifer McEachron, Carolyn Chatterton, Victoria Hastings, Constantine Gorelick, Katherine Economos, Yi-Chun Lee, Marguax J. KanisAbstractMetastasis to bone (BM) is an uncommon manifestation of advanced endometrial cancer (EC). The present study will review the clinicopathologic features of a cohort of patients with EC and BM. We conducted a multi-center retrospective review of patients with EC and BM. Demographic and clinical information was extracted from the medical records. Survival outcomes were determined using Kaplan-Meier Curves. Final analysis included 10 patients. The median age was 65 years (range 31-71). 80% had FIGO stage III/IV disease. The most common site of BM was the spine (66%). All patients presented with extraosseous dissemination at the time of diagnosis of BM and 70% were found to have multiple sites of BM. 80% of patients were diagnosed with BM in the recurrent setting. The median time to diagnosis of bone recurrence was 14 months (range: 0-44). Median survival after diagnosis of BM was 11 months (range: 1-22 months). Patients with endometrioid histology and single site of bone metastasis experienced improved survival (p=0.04 and p=0.05, respectively). Eight patients had immunohistochemistry or molecular tumor profiles available for review. Seven of these patients (87.5%) were found to have microsatellite instability (MSI). The most common mutation was hyp...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research